Affiliation:
1. AdventHealth Translational Research Institute Orlando Florida
2. Novo Nordisk A/S Søborg Denmark
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference4 articles.
1. A model‐based simulation of glycaemic control and body weight when switching from semaglutide to 3.0‐ and 4.5‐mg doses of once‐weekly dulaglutide
2. An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
3. ConsoliA BainSC DaviesM et al.Semaglutide provides sustained reductions in body weight over 2 years in subjects with type 2 diabetes (SUSTAIN 6).European Association for the Study of diabetes(EASD) virtual meeting 2017; Abstract 4.https://www.easd.org/virtualmeeting/home.html#!resources/semaglutide‐provides‐sustained‐reductions‐in‐body‐weight‐over‐2‐years‐in‐subjects‐with‐type‐2‐diabetes‐sustain‐6. Accessed December 8 2021.
4. Network meta-analyses should be the highest level of evidence in treatment guidelines